+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 6 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
S

Actively Recruiting

Researchers are evaluating the safety and effectiveness of NNC0487-0111 for adults with excess body weight. This clinical trial compares the study drug against a placebo, both given as weekly injections under the skin, to see how well they help with weight loss. Participants will be randomly assigned to receive one of four doses of NNC0487-0111 or a matching placebo once a week. Both groups will follow a reduced-calorie diet and increase physical activity. The injections are given using pre-filled pen devices on the thigh, abdomen, or upper arm. During the study, participants will have their body weight and other health measures tracked from the start through week 84 and up to week 136. Researchers will monitor waist size, blood pressure, blood sugar levels, cholesterol, and quality of life. Safety will be assessed by counting any side effects through week 140. The total study duration includes treatment and follow-up visits.

Age: 18Years +All GendersPhase 3
72 locations
E

Actively Recruiting

Researchers are evaluating zenagamtide, an oral medication, to determine its safety and effectiveness in helping adults with excess body weight lose weight. This phase 3 clinical trial compares zenagamtide against a placebo to understand its impact as part of a treatment for overweight and obesity. The study involves participants aged 18 and older who will be randomly assigned to different treatment groups. Participants will receive either one of five dose levels of zenagamtide or a placebo, both taken orally once daily. These treatments are combined with a reduced-calorie diet and increased physical activity to support weight loss efforts. The study treatment period lasts up to 76 weeks, during which participants follow the lifestyle changes alongside the medication or placebo. Throughout the study, participants will be monitored regularly to assess changes in body weight as the primary outcome, alongside secondary measures like waist circumference and systolic blood pressure. Safety and adherence will also be tracked. The total participation duration extends up to about 76 weeks, with ongoing evaluations to understand the treatment effects over this timeframe.

Age: 18Years +All GendersPhase 3
41 locations
S

Actively Recruiting

Researchers are evaluating a multi-level approach called the Science of Service Laboratory to increase the use of contingency management for stimulant use among people receiving medication for opioid use disorder. This study focuses on public sector addiction specialty treatment programs and aims to improve both how contingency management is implemented and patient outcomes. The trial addresses the gap in using contingency management, an evidence-based intervention for stimulant addiction, within opioid treatment programs. The study uses a stepped wedge design where addiction programs are randomized in cohorts to receive the Science of Service Laboratory strategy. This approach includes didactic training with workshops and coaching calls, performance feedback through practice sessions and electronic medical record data, and external facilitation with monthly calls. Programs start with usual care and then transition to the implementation strategy, allowing comparison before and after the intervention. Participants include opioid treatment program counselors providing psychosocial support and patients newly started on medication for opioid use disorder who also use stimulants. Data collected include de-identified electronic medical records on contingency management delivery and patient outcomes, alongside staff reports on implementation factors. Primary outcomes focus on changes in the percentage of patients receiving contingency management and counselors delivering it over 10 months. Secondary outcomes include stimulant abstinence measured by toxicology screens and the number of contingency management sessions.

Age: 18Years +All GendersPhase Not Applicable
9 locations
S

Actively Recruiting

Researchers are evaluating two treatment options for people with type 2 diabetes who also have established or high-risk atherosclerotic cardiovascular disease ASCVD. This clinical trial aims to compare the total number of heart, kidney, and death events between treatments using sodium-glucose cotransporter-2 inhibitors SGLT2i and glucagon-like peptide-1 receptor agonists GLP-1 RA. The study involves 6,000 participants and seeks to better understand how these medications affect health outcomes in this population. Participants will be randomly assigned to receive either an SGLT2 inhibitor canagliflozin, dapagliflozin, or empagliflozin or a GLP-1 receptor agonist dulaglutide, liraglutide, or semaglutide, all of which have shown cardiovascular benefits. The study is open label, meaning both participants and researchers know which treatment is given. Treatment assignment is balanced evenly between the two groups, and participants will continue their assigned therapy throughout the study. During the trial, researchers will monitor participants for events including heart attacks, strokes, arterial revascularization, hospitalizations for heart failure, kidney failure, kidney transplants, and death. Follow-up will last for an average of about three years. Data will be collected through medical records and electronic health information, with ongoing tracking of health status and treatment adherence to assess the total number of these cardiovascular and kidney-related events.

Age: 40Years - 80YearsAll GendersPhase 4
36 locations
C

Actively Recruiting

Researchers are studying perinatal health outcomes in Rhode Island, focusing on improving maternal and infant health by addressing social determinants of health SDOH such as food, housing, and transportation. The project aims to reduce adverse outcomes and racial disparities by integrating hospital services with community health workers, doulas, and community organizations. This effort is structured as a stepped wedge cluster randomized trial across six prenatal clinics over four years. The study involves implementing the Community-based Maternal Support Services COMSS program, which includes universal screening for risk factors at multiple prenatal and postpartum visits. Patients who screen positive receive coordinated care from care managers and community health workers, including doula care and referrals to address social needs. The intervention is introduced sequentially to all clinics, and data will be collected before and after the program to evaluate its impact. Participants will undergo screenings at their first prenatal visit, second and third trimesters, delivery, and 2-6 weeks postpartum. Those identified with risks will receive ongoing support and follow-up, with care continuing until at least three months postpartum before transitioning to primary care. Researchers will assess outcomes such as rates of severe maternal morbidity and mortality, cesarean births, prenatal care adequacy, postpartum depression screening, substance abstinence during pregnancy, infant death, and preterm birth.

All AgesFEMALEPhase Not Applicable
7 locations